Aegis Capital Comments on Inovio (INO) Following Q2 Results; Cash Position Remains 'Solid'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Aegis Capital Comments on Inovio (INO) Following Q2 Results; Cash Position Remains 'Solid'

Inovio Pharmaceuticals (INO) Posts Narrower than Expected Q2 Loss of 18c/Share

August 11, 2014 9:17 AM EDT

Inovio Pharmaceuticals, Inc. (AMEX: INO) reported Q2 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $1.8 million.

Dr. J. Joseph Kim, President and CEO, said, "Our second quarter marked a historical... More